|
EQS-News: Biotest AG
/ Key word(s): Regulatory Admission
PRESS RELEASE
US Food and Drug Administration FDA accepts marketing authorization application for immunoglobulin Yimmugo
Dreieich, 7 September 2023. Biotest AG announced today that the Biologics License Application (BLA) for the polyspecific immunoglobulin preparation Yimmugo (IgG Next Generation) has been accepted for review by the U.S. Food and Drug Administration (FDA) after the 60-day validation phase. With this filing notification the marketing authorization application will enter the next phase, in which the application dossier will be subjected to an in-depth substantive review. The marketing authorization application covers the indication primary immunodeficiencies (PID). After receiving approval, Biotest plans to expand the indication to include chronic primary immune thrombocytopenia (ITP). "We are pleased that the FDA has accepted our Yimmugo dossier for review, which reflects the completeness and required level of detail of the submitted application dossier. This is an important milestone in the approval process for Yimmugo. Over the next ten months, we will convince the FDA that Yimmugo is safe, effective and manufactured to the highest quality standards and also meets the FDA's requirements," said Dr. Reto Bisaz, the manager responsible for the US approval. The FDA's decision on the marketing authorization application of Yimmugo is expected on June 29, 2024. Biotest's new immunoglobulin is manufactured in an innovative production process and is the main product of the new Biotest Next Level production facility. The new production facility, which uses state-of-the-art technologies, represents Biotest's increased commitment to the global immunoglobulin market.
About Yimmugo (IgG Next Generation) Yimmugo is a newly developed polyvalent immunoglobulin G preparation from human blood plasma for intravenous administration (IVIG). The sugar-free ready-to-use solution is approved for replacement therapy in primary antibody deficiency syndromes and secondary immune deficiency, as well as for immunomodulation in autoimmune diseases such as ITP, GBS, CIDP, MMN and Kawasaki’s disease. Yimmugo is the first approved product from the new Biotest Next Level production facility. The modern production process stands for highest product quality and an extremely responsible use of resources.
About Biotest: Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 2,300 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange. Since May 2022, Biotest has been a part of the Grifols Group, based in Barcelona, Spain (www.grifols.com).
Dr Monika Buttkereit Phone: +49-6103-801-4406
PR contact Dirk Neumüller Phone: +49-6103-801-269 Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.com Ordinary shares: securities’ ID No. 522720; ISIN: DE0005227201
Disclaimer
07.09.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
| Language: | English |
| Company: | Biotest AG |
| Landsteinerstraße 5 | |
| 63303 Dreieich | |
| Germany | |
| Phone: | 0 61 03 - 8 01-0 |
| Fax: | 0 61 03 - 8 01-150 |
| E-mail: | ir@biotest.com |
| Internet: | www.biotest.de |
| ISIN: | DE0005227235, DE0005227201 |
| WKN: | 522723, 522720 |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1720533 |
| End of News | EQS News Service |
|
|
1720533 07.09.2023 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
